{"organizations": [], "uuid": "77d27c808be83e6e4dccc8420cdbfba987c37702", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfenex-and-nt-pharma-enter-into-a/brief-pfenex-and-nt-pharma-enter-into-a-development-and-license-agreement-for-pfenexs-pf708-therapeutic-equivalent-candidate-to-forteo-idUSFWN1RV0Y4", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T00:05:00.000+03:00", "replies_count": 0, "uuid": "77d27c808be83e6e4dccc8420cdbfba987c37702"}, "author": "", "url": "https://www.reuters.com/article/brief-pfenex-and-nt-pharma-enter-into-a/brief-pfenex-and-nt-pharma-enter-into-a-development-and-license-agreement-for-pfenexs-pf708-therapeutic-equivalent-candidate-to-forteo-idUSFWN1RV0Y4", "ord_in_thread": 0, "title": "BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo", "locations": [], "entities": {"persons": [{"name": "pfenex", "sentiment": "none"}], "locations": [], "organizations": [{"name": "pf708 therapeutic equivalent candidate to forteo reuters", "sentiment": "none"}, {"name": "reuters) - china nt pharma group co ltd", "sentiment": "none"}, {"name": "forteo", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - China NT Pharma Group Co Ltd:\n* PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX’S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®\n* PFENEX INC - PFENEX RECEIVED A PAYMENT OF $2.5 MILLION UPON SIGNING OF AGREEMENT\n* PFENEX INC - PFENEX MAY BE ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS OF UP TO $22.5 MILLION BASED ON ACHIEVEMENT OF DEVELOPMENT, SALES-RELATED MILESTONES\n* PFENEX INC - PFENEX MAY ALSO BE ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON NET PRODUCT SALES Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-19T00:05:00.000+03:00", "crawled": "2018-04-19T00:22:19.011+03:00", "highlightTitle": ""}